Intra-Biotech Consolidation in Europe? Not Affordable.
Executive SummaryBankers and consultants have long been urging the virtues of consolidation onto a financially strapped biotech industry. But few companies on either side of the Atlantic have been listening.
You may also be interested in...
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.